The prevalence of PIM-1 kinase in these cancers, coupled with its crucial role in disease progression, underscores the importance of targeting PIM-1 for therapeutic interventions in prostate cancer and potentially other hematological malignancies where its expression is dysregulated (Asati et al., 2019). This evidence concerns the gene PIM1 and cancer.